Treatment of Intrauterine Adhesions and Its Distribution of Genital Tract Flora

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-01

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to investigate the treatment of intrauterine adhesion and the factors influencing its prognosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Outcome and Influence Factors of Assisted Reproductive Therapy in Patients With Cesarean Scar Uterus.

NCT04070222

Infertile Patients With Previous Live Birth

UNKNOWN

Three-dimensional Ultrasound Applying in Assessment of Intrauterine Adhesions

NCT04930913

Intrauterine Adhesion

UNKNOWN

Efficacy and Safety of Crosslinked Hyaluronan Gel for Preventing Intrauterine Adhesion

NCT02220621

Intrauterine Adhesion

COMPLETED NA

The Efficacy of A New Crosslinked Hyaluronan Gel in Prevention of Intrauterine Adhesion

NCT03353909

Intrauterine Adhesion

COMPLETED NA

Development of a Bioabsorbable Medical Device for the Prevention of Postoperative Intra-uterine Adhesions.

NCT02328742

Infertility Abortion, Spontaneous Embryo Implantation, Delayed

WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Intrauterine adhesion, also known as Asherman's syndrome, is the partial or complete occlusion of the uterine cavity as a result of endometrium damage. Most intrauterine adhesions patients manifest amenorrhea, reduced menstrual pattern, infertility, and intrauterine growth restriction, which seriously affect their reproductive health.It is well established that the formation of intrauterine adhesion likely involves hypoxia, reduced neovascularization, and altered expression of adhesion associated cytokines, but the exact mechanisms are not well understood. Although excessive curettage is considered the primary cause, intrauterine adhesion is known to be associated with diverse non-traumatic factors, such as postabortal sepsis, puerperal sepsis and infections. Intrauterine adhesion separation surgery is the gold standard for the treatment of uterine adhesion. Although the success rate is as high as 95%, the patients with moderate or severe uterine adhesion have severe damage to the endometrial basement, poor regeneration of endometrial and gland, poor tolerance of endometrial and poor clinical prognosis. Even if all kinds of anti-adhesion measures are used comprehensively, the postoperative recurrence rate of patients with moderate and severe uterine adhesion is high.Therefore this study was conducted to investigate whether intrauterine lavage or intrauterine gel-injection therapy after surgery could reduce the recurrence of intrauterine adhesion, promote the endometrial growth and repair and improve the menstruation and reproductive prognosis for severe intrauterine adhesion, and we hypothesize that intrauterine adhesion may be related to changes in microbial flora in the reproductive tract.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intrauterine Adhesions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

Control group( Intrauterine patients) do not apply intrauterine lavage therapy or intrauterine gel-injection therapy after surgery.

Group Type NO_INTERVENTION

No interventions assigned to this group

Intrauterine lavage therapy group

Intrauterine lavage therapy group apply intrauterine lavage therapy after surgery.

Group Type EXPERIMENTAL

Intrauterine lavage therapy

Intervention Type DRUG

Intrauterine lavage treatment was performed within 3 to 7 days after the first menstrual period after surgery.

Intrauterine gel-injection therapy group

Intrauterine gel-injection therapy group apply intrauterine gel-injection therapy after surgery.

Group Type EXPERIMENTAL

Intrauterine gel-injection therapy

Intervention Type DRUG

Intrauterine gel-injection treatment was performed within 3 to 7 days after the first menstrual period after surgery.

Healthy control group

Healthy control group 1)have regular menstrual cycles,diagnostic hysteroscopy with endometrial biopsy and laparoscopy as part of their infertility diagnostic work-up prior to IVF, hysteroscopy and subsequent pathological results having shown no abnormality in the uterine cavities and abdominal cavity.2) had male partners who were infertile and diagnosed with defective sperm function,such as asthenozoospermia, oligoasthenozoospermia, severe oligoasthenozoospermia and azoospermia, defined according to guidelines published by the World Health Organization.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intrauterine lavage therapy

Intrauterine lavage treatment was performed within 3 to 7 days after the first menstrual period after surgery.

Intervention Type DRUG

Intrauterine gel-injection therapy

Intrauterine gel-injection treatment was performed within 3 to 7 days after the first menstrual period after surgery.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pre-operative adhesion score was ≥5
* The prior menstrual cycle was regular, and the sex hormone was normal
* Patients had fertility requirement
* Male semen examination showed normal
* There were no severe systemic diseases, and no contradictions to aspirin, estrogen and surgery

* regular menstrual cycles,diagnostic hysteroscopy with endometrial biopsy and laparoscopy as part of their infertility diagnostic work-up prior to IVF, hysteroscopy and subsequent pathological results having shown no abnormality in the uterine cavities and abdominal cavity
* the healthy women recruited had male partners who were infertile and diagnosed with defective sperm function,such as asthenozoospermia, oligoasthenozoospermia, severe oligoasthenozoospermia and azoospermia, defined according to guidelines published by the World Health Organization.

Exclusion Criteria

* Pre-operative adhesion score was \<5
* Prior menstrual cycle was irregular and sex hormone was abnormal, or patients had endocrine factors that caused amenorrhea, menstrual reduction and infertility
* Patients had no fertility requirement
* Patients(experimental group and control group) had male factor infertility
* Patients had contradictions to estrogen and aspirin such as cancers (breast cancer and endometrial cancer), thrombotic diseases, allergy to antipyretic analgesics, severe liver injury, hypoprothrombinemia, vitamin K deficiency, hemophilia, thrombocytopenia, gastric or duodenal ulcer and asthma.
* refuse Endometrial biopsy
* Vaginal discharge abnormal, or suspected vaginitis or pelvic inflammatory disease, or using antibiotics.

Minimum Eligible Age

20 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes